Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Dermatologic 2CNS 2Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 250Uveal Melanoma 29Neoplasm Metastasis 22Skin Neoplasms 17Brain Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Merkel Cell 10Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Triple Negative Breast Neoplasms 7Carcinoma, Hepatocellular 7Uterine Cervical Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Basal Cell 4Sarcoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2

Interventions

Nivolumab 3fludarabine 2Ipilimumab 2tipifarnib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1pembrolizumab 1iso-sulfan blue 1fludarabine phosphate 1dostarlimab 1bempegaldesleukin 1Stem Cell Transplantation 1Sirolimus 1Mesna 1Melphalan 1Mass Spectrometry 1LY2940680 1Immunologic Techniques 1Cyclophosphamide 1Cryotherapy 1Cryosurgery 1Chromatography, High Pressure Liquid 1CTLA-4 Antigen 1Busulfan 1BI 2536 1Alemtuzumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Ipilimumab × Dermatologic × Clear all
NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡